<DOC>
	<DOC>NCT02207218</DOC>
	<brief_summary>This study is conducted in Asia. The aim of this study is to evaluate the safety and efficacy of NovoEight® (recombinant factor VIII) in patients with haemophilia A in Japan in the setting of routine clinical practice.</brief_summary>
	<brief_title>To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Informed consent obtained before any studyrelated activities. Studyrelated activities are any procedure related to recording of data according to the protocol Male and female patients with the diagnosis of haemophilia A Age range is 0 year and above A decision to initiate treatment with commercially available NovoEight® has been made by the patient/parent and the physician Known or suspected allergy to study product(s) or related products Previous participation in this study. Participation is defined as informed consent obtained Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>